58th Annual Meeting of the American Academy of Neurology: Atomoxetine Benefits Attention-Deficit/Hyperactivity Disorder and Comorbid Tourette Syndrome
In: Main
7 Apr 2010
Atomoxetine Benefits Attention-Deficit/Hyperactivity Disorder and Comorbid Tourette Syndrome
Speaker: Thomas J. Spencer, MD, Associate Professor, Department of Psychiatry, Harvard Medical School, and Assistant Director, Pediatric Psychopharmacology Clinic, Department of Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts
Atomoxetine (Strattera tablet, Lilly), a nonstimulant indicated for attention-deficit/hyperactivity disorder (ADHD), has been shown to be safe, well tolerated, and effective for children with ADHD and comorbid Tourette syndrome by treating ADHD symptoms without exacerbating tic symptoms. Because the psychostimulants traditionally used to treat ADHD sometimes trigger or worsen motor or vocal tics in patients with ADHD and Tourette syndrome, a study was performed to examine the change in severity of tics and symptoms of ADHD during atomoxetine treatment.
58th Annual Meeting of the American Academy of Neurology: Donepezil and Severe Alzheimer’s Disease
In: Main
6 Apr 2010Donepezil and Severe Alzheimer’s Disease
Speaker: Bengt Winblad, MD, PhD, Professor and Director, Neurotec Department, Division of Geriatrics, Alzheimer’s Disease Research Center, Karolinska Institute and Karolinska University Hospital, Huddinge, Sweden
Donepezil (Aricept canadian, Eisai/Pfizer), well known for its value in the treatment of patients with mild-to-moderate Alzheimer’s disease (AD), has shown substantial benefits in cognition and clinical global improvement in patients with severe AD.
58th Annual Meeting of the American Academy of Neurology: New Sumatriptan Formulation for Acute Migraine
In: Main
5 Apr 2010New Sumatriptan Formulation for Acute Migraine
Speaker: Roger Cady, MD, Director, Headache Care Center and Primary Care Network, Springfield, Missouri
A new formulation consisting of a fixed-dose, single tablet containing sumatriptan succinate 85 mg with RT Technology (Suma RT) with naproxen sodium 500 mg (NAP) (Suma RT/NAP) (Trexima, GlaxoSmithKline/Pozen) showed superior results in treating acute migraine pain compared with either the separate components or placebo. (Trexima is the proposed brand name for the combination of generic sumatriptan [Imitrex medication], formulated with RT Technology, and naproxen canadian) Significantly more patients were “satisfied” or “very satisfied” with the combination compared with Suma RT, NAP, or placebo.
58th Annual Meeting of the American Academy of Neurology: Rotigotine Patch in Parkinson’s Disease
In: Main
4 Apr 2010Rotigotine Patch in Parkinson’s Disease
Speaker: Peter LeWitt, MD, Professor of Neurology and Psychiatry, Wayne State University School of Medicine, Detroit, Michigan, and Clinical Neuroscience Center, South-field, Michigan
The rotigotine transdermal system (Neupro, Schwarz Pharma), a non-ergolinic dopamine receptor agonist, when administered once daily, has been shown to be safe, well tolerated, and effective in patients with late-stage Parkinson’s disease who have not responded to levodopa. The patch provided statistically significant reductions in “off” time as an adjunct to levodopa without an increase in “on” time in patients with troublesome dyskinesias. (After a number of years of treatment with levodopa, about 80% of patients begin to experience fluctuations in their response—the “on-off” effect.)
58th Annual Meeting of the American Academy of Neurology
In: Main
3 Apr 2010
Interferon Beta-1b for Multiple Sclerosis
Speaker: Ludwig Kappos, MD, Professor of Neurology and Clinical Neuroimmunology, Department of Neurology and Research, University of Basel and University Hospital Basel, Basel, Switzerland
In a large-scale European clinical trial, interferon beta-1b (IFN (5-1b) (Betaseron, Schering AG, Germany) was effective, safe, well tolerated, and well accepted for patients with a first clinical event suggestive of multiple sclerosis (MS).
Pressure Builds to Untie the FDA’s Hands on Generics
In: Main
2 Apr 2010
Merck’s decision to reduce the price of cholesterol-lowering generic simvastatin (Zocor drug) in the face of first-time generic competition from Teva Pharmaceuticals may be red meat for the congressional advocates of faster approval of generic versions of both chemical and biotech innovator drugs. And those forces may get a bigger boost still when Sandoz announces its pricing strategy for Omni-trope, an ostensible generic copy of Pfizer’s bioengineered growth hormone Genotropin—although the Food and Drug Administration (FDA) calls it a follow-on protein. The FDA approved Omni-trope at the end of May, the first time the agency approved a generic company’s biopharmaceutical product based on an abbreviated 505(b)(2) application that was submitted by a generic company.
- No Comments
- Tags: Pressure Builds
Foot Soldiers for EBM
In: Main
1 Apr 2010We are all familiar with them— the nattily clad, always smiling, generally attractive group of men and women who make up the more than 90,000 salespeople in the U.S. and who work as “detailers” for the pharmaceutical industry. Many of our institutions have strict limitations on the access that these detailers can have to key decision-makers. It is likely that almost every P&T committee member signs an appropriate conflict-of-interest statement each year, outlining his or her dual commitments to the institution and possibly also to a large array of biopharmaceutical companies.
- No Comments
- Tags: Foot Soldiers
About this blog
Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.
Photostream
Categories
- Anesthesia (109)
- Dental treatment (46)
- Disease (12)
- Drug (15)
- Health (49)
- Main (71)
- No comments
- FARS and FFIRS
- Meals at Medical Meetings: Mixed Messages
- Evidence-Based Herbal Medicine
- The American College of Cardiology: Beta Blockade in Severe Heart Failure and Extremely Depressed LVEF
- The American College of Cardiology: Antiplatelet Therapy for In-Stent Restenosis Post-Brachytherapy
- The American College of Cardiology
- A Cost Analysis of Switching Calcium Channel Blockers: DISCUSSION
- A Cost Analysis of Switching Calcium Channel Blockers: RESULTS
- A Cost Analysis of Switching Calcium Channel Blockers: Study Design
- A Cost Analysis of Switching Calcium Channel Blockers